ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly erbitux (cetuximab) — Worldwide revenue ($M) [legacy separate disclosure] ($M)
Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization)
Latest, FY2024
627
Period ended Dec 31, 2024
Change on a year earlier
+5.2%
597 in FY2023
History
17 years
Since FY2008
Sources
13
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Erbitux (cetuximab) — Worldwide revenue ($M) [legacy separate disclosure] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 627 | +5.2% | Form 10-K FY2024 (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 597 | +5.3% | Form 10-K FY2023 (filed 2024-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 567 | +3.3% | Form 10-K FY2022 (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 548 | +2.2% | Form 10-K FY2021 (filed 2022-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 536 | -15.6% | Form 10-K FY2020 (filed 2021-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 635 | +18.5% | Form 10-K FY2019 (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 536 | -2.2% | Form 10-K (filed 2019-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 548 | -6.6% | Form 10-K (filed 2019-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 587 | +21.0% | Form 10-K (filed 2019-02-19) ↗ |
| FY2015 | Dec 31, 2015 | 485 | +29.9% | Form 10-K (filed 2016-02-19) ↗ |
| FY2014 | Dec 31, 2014 | 373 | -0.1% | Form 10-K (filed 2015-02-19) ↗ |
| FY2013 | Dec 31, 2013 | 374 | -5.9% | Form 10-K (filed 2014-02-19) ↗ |
| FY2012 | Dec 31, 2012 | 397 | -3.0% | Form 10-K (filed 2013-02-21) ↗ |
| FY2011 | Dec 31, 2011 | 409 | +6.0% | Form 10-K (filed 2012-02-24) ↗ |
| FY2010 | Dec 31, 2010 | 386 | -1.2% | Form 10-K (filed 2011-02-22) ↗ |
| FY2009 | Dec 31, 2009 | 391 | +1,229.3% | Form 10-K (filed 2011-02-22) ↗ |
| FY2008 | Dec 31, 2008 | 29.4 | – | Form 10-K (filed 2011-02-22) ↗ |
Breakdown
What makes up erbitux (cetuximab) — worldwide revenue ($m) [legacy separate disclosure]
Cite this data
StockData. (2026). Eli Lilly Erbitux (cetuximab) — Worldwide revenue ($M) [legacy separate disclosure] ($M), annual FY2008–FY2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_erbitux_ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.